Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Lung Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Severe Asthma
Interventions: Alair System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 23
States / cities: Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 18 more

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: SNS-101 (anti-VISTA), Cemiplimab; Drug
Lead sponsor: Sensei Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cancer, Solid Tumor
Interventions: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer; Drug
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Duarte, California • Farmington, New Mexico

Conditions: Lung Cancer
Interventions: rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Dublin, California

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Apieron Insight eNO monitor; Device
Lead sponsor: Apieron; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Mission Viejo, California • San Jose, California • Glastonbury, Connecticut + 9 more

Conditions: Asthma
Interventions: Electronic Medication Monitors on ICS and SABA - Active Mode, Electronic Medication Monitors on ICS and SABA - Silent Mode, Asthma App Tracking of ICS/SABA Usage - Active Mode, Asthma App Tracking of ICS/SABA Usage - Silent Mode, NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes, NorthShore Connect Real Time ICS and SABA Usage Feedback - No, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No; Behavioral
Lead sponsor: Endeavor Health; Other
Eligibility: 25 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Embolism
Interventions: Intravascular Filter Device; Device
Lead sponsor: Rex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Burlingame, California • Newark, Delaware • Washington D.C., District of Columbia + 7 more

Conditions: Asthma
Interventions: Benralizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
Interventions: MyVoice:CF; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: PLACEBO, MEDI528 9 mg/kg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more

Conditions: Pleural Effusion, Lung Consolidation
Interventions: Lung Ultrasound Scan; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: Not listed
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
Interventions: Not listed
Lead sponsor: Wilkes University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Infant Respiratory Distress Syndrome, Respiratory Insufficiency, Apnea of Prematurity
Interventions: Nasal high frequency ventilation; Other
Lead sponsor: Tarah T Colaizy; Other
Eligibility: 7 Days to 3 Months
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Interventions: Petosemtamab + Pembrolizumab; Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: St. Petersburg, Florida • Long Island City, New York • Chattanooga, Tennessee + 3 more

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Tezacaftor/Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Birmingham, Alabama • Oakland, California • San Diego, California + 30 more

Conditions: COVID-19
Interventions: Practice details; Other
Lead sponsor: Al-Azhar University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Albertson, New York

Search by objective public record fields.

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Bronchial Thermoplasty in Severe Persistent Asthma

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Targeting Right Ventricle in Pulmonary Hypertension Gilead

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

Influenza Vaccine in Lung Transplant Patients - Antibody

Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

RexMedical- Option* Vena Cava Filter IDE Study

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

MyVoice:CF Decision Aid for Women With Cystic Fibrosis

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Point of Care Ultrasound Lung Artificial Intelligence (AI) Validation Data Collection Study

Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19

Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

COVID-19 Endoscopy Survey